AngioDynamics Receives 'Moderate Buy' Rating from Analysts

Analysts see potential in the medical device company despite recent stock performance.

Mar. 29, 2026 at 8:19am

Got story updates? Submit your updates here. ›

A high-contrast, close-up image of the intricate mechanical components and engineering inside an AngioDynamics medical device, conveying a sense of the company's technological sophistication and manufacturing expertise.The complex inner workings of AngioDynamics' innovative medical devices represent the company's technological prowess and commitment to precision engineering.Latham Today

AngioDynamics, Inc. (NASDAQ:ANGO) has received a consensus 'Moderate Buy' rating from the five brokerages covering the company, according to Marketbeat Ratings. The average 12-month price target among analysts is $19.33. While one analyst has a 'sell' recommendation, three have 'buy' ratings and one has a 'strong buy' on the stock.

Why it matters

AngioDynamics is a medical technology company that develops minimally invasive devices for vascular access, peripheral vascular intervention, and interventional oncology. The company's stock performance has been mixed recently, so this 'Moderate Buy' consensus from analysts suggests they see potential in the business despite the recent challenges.

The details

The analysts' ratings and price targets for AngioDynamics are based on the company's product portfolio, market positioning, and financial performance. Wall Street Zen lowered their rating to 'hold' in December, while Zacks Research upgraded the stock to 'strong buy' in January. Institutional investors and hedge funds own 89.43% of AngioDynamics' shares.

  • AngioDynamics released its latest financial results on March 29, 2026.
  • The analysts' consensus 'Moderate Buy' rating was reported on March 29, 2026.

The players

AngioDynamics, Inc.

A medical technology company headquartered in Latham, New York that develops minimally invasive medical devices for vascular access, peripheral vascular intervention, and interventional oncology.

Wall Street Zen

An equities research firm that lowered its rating on AngioDynamics to 'hold' in December.

Zacks Research

An equities research firm that upgraded AngioDynamics to 'strong buy' in January.

Got photos? Submit your photos here. ›

The takeaway

The 'Moderate Buy' consensus from analysts suggests they see potential in AngioDynamics despite the company's recent stock performance challenges. The ratings and price targets indicate analysts believe the medical device maker's product portfolio and market positioning could drive future growth, though some concerns remain.